On behalf of the team at Arrinex Inc. we would like to express our gratitude and appreciation for the level of Professionalism and dedication that the Sacramento ENT research team has provided.

As a sponsor selecting sites, we often have to make difficult choices between academic research centers that bring domain specific knowledge but are slow to enroll study subjects, non-academic practices that may not have staff that is adequately trained in the execution of clinical trials, or clinical research organizations which may not be able to bring in a high volume but with less domain experience, and certainly no long-term relationship with enrolled study subjects. Using Sacramento ENT for clinical research, we get the benefits of domain specific knowledge , high enrollment, adequately trained staff and investigators that have a vested interest in the long-term care of the study subjects.

Your team brings the best combination of what as a sponsor, we need in the execution of quality clinical trials. We need more sites like yours in the ENT industry.

Thank you for your continued support of our current studies and those we hope to partner with you in the future.

I would like to express my appreciation on behalf of Genentech, for the outstanding job you and your research staff are doing in the recruitment of patients and execution of trial conduct in our POLYP study. "A phase III, randomized , multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with chronic rhinosinusitis with nasal polyps." We recognize the difficulty of identifying patients for this study, given the severe degree of nasal polypsis required to meet inclusion criterion, among other multiple factors. In fact, with the 8 subjects that you have already recruited thus far, you are our top recruiting site to date! This is especially remarkable given the smooth execution at your site, the fact that you have had a relatively low screen failure rate, and that we will ultimately activate in excess of 120 site globally.

In addition, we appreciate your insightful comments at our recent Investigator Meeting regarding the centralized reading of nasal polyps scores and other trial factors. It's been a pleasure to work with you, and we will look forward to further contributions from your site.

Congratulations on being the first in the nation to enroll a patient in the ASCEND trial last week! This is a critical milestone for Intersect ENT and also an important step in advancing care for chronic rhinosinusitis patients. Kudos!

On behalf of my entire team, I wanted to personally thank you for your partnership in our clinical programs over the years. Under Dr Ow's and your leadership, together we have established a new standard for clinical science in the Otolaryngology field. Conducting multicenter, randomized, controlled studies were no the norm in ENT when we started working with you and like-minded clinicians years ago. It is clinical sites like yours that have the tenacity, capabilities and ability to deliver high quality data that have made these advancements possible. Thank you.

Please pass on our congratulations and thanks to the entire team. We so appreciate your strong patient relationships, hard work, and attention to detail. We literally couldn't do what we do without you and the Sacramento ENT team.

Just wanted to take a moment to thank you and the team at Sac ENT for your excellent support of the ADEPT and OTTER clinical studies. As you know, we specifically reached out to Dr Randy Ow to be an investigator in our studies due to his great reputation within the ENT research community as a research leader who can successfully recruit patients and deliver quality research outcomes and data. This level of commitment and expertise is critical to the generation of important scientific evidence regarding therapies for ENT patients, and to enable FDA approval for new therapies.

We also selected Sac ENT because we were familiar with you and your team's skills in supporting new technology research and had confidence that, through your management of the studies, the study conduct and documentation would be compliant with FDA regulations and IRB requirements and would pass FDA's scrutiny during an audit. We appreciate the level of professionalism and compassion that you and Marcy Adame demonstrate through your patient interactions during the research process including consenting , procedure and study visits. Marcy and Oleg Kolesnikov also do an excellent job in data collection and regulatory documentation in a manner that will withstand an FDA audit, and in management of the study product and logistics.

A special note of a appreciation to you and Marcy, for being so responsive for all the necessary communications regarding study conduct, scheduling and logistics, and to Dr Ow for never hesitating to reach out to us directly with any questions or concerns.
We look forward to continuing to work with you in the OTTER in future studies.

Lyra Therapeutics announced the completion of enrollment in Beacon on 06Feb2023.

This letter is to recognize Dr. Ow and his clinical research team's significant contributions to the Beacon study.

Congratulations on being the top enroller in Beacon! On behalf of Lyra, I would like to congratulate you and your research team on this accomplishment. Lyra Therapeutics' clinical team is grateful for the collaboration.